Skip to content

US · LXEO · BIOTECHNOLOGY

Lexeo Therapeutics, Inc. Common Stock (LXEO) intrinsic value and stock valuation

$2.96as of 2026-11-21 · Mkt cap 349.42M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Lexeo Therapeutics, Inc. Common Stock DCF and intrinsic value

InvestorsCraft values LXEO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LXEO’s statements →

Lexeo Therapeutics, Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York City, NY 10010 lexeotx.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$0.00
20202025
Net income
-$-99.96M
20202025
Free cash flow
-$-98.96M
20202025
Total equity
$246.7M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$650K$1.66M
Operating income-$-109.26M-$-105.77M-$-68.51M-$-60.51M-$-50.64M
Net income-$-99.96M-$-98.33M-$-66.39M-$-59.28M-$-50.62M
EPSd-$-1.86M-$-3.09M-$-2.49M-$-2.36M-$-2.01M
Operating cash flow-$-98.56M-$-81.15M-$-59.5M-$-54.56M-$-44.18M
Capital expenditure-$-400K-$-480K-$-170K-$-900K-$-190K
Free cash flow-$-98.96M-$-81.63M-$-59.66M-$-55.46M-$-44.37M
Total assets$268.7M$146.9M$139.8M$97.1M$136.9M
Total debt$7.89M$9.92M$11.6M$13.5M$0.00
Net debt-$-55.11M-$-25.09M-$-109.83M-$-63.85M-$-135.86M
Total equity$246.7M$116.8M$113.5M-$-112.95M-$-55.6M
Cash and short-term investments$181.8M$121.5M$121.5M$77.3M$135.9M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$650K$1.66M
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$650K$1.66M
Research and development expenses$63.8M$74.1M$53.1M$49.2M$45.1M
Selling, general and administrative expenses$45.5M$31.7M$15.4M$12M$7.17M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$109.3M$105.8M$68.5M$61.2M$52.3M
Cost and expenses$109.3M$105.8M$68.5M$61.2M$52.3M
Interest income$6.13M$7.56M$2.87M$1.32M$10K
Interest expense$210K$110K$200K$90K$0.00
Depreciation and amortization$2.08M$2M$1.84M$1.15M$10K
Ebitda-$-97.68M-$-96.19M-$-64.35M-$-58.04M-$-50.61M
Operating income-$-109.26M-$-105.77M-$-68.51M-$-60.51M-$-50.64M
Total other income/expenses, net$9.3M$7.43M$2.12M$1.23M$10K
Income before tax-$-99.96M-$-98.33M-$-66.39M-$-59.28M-$-50.62M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-99.96M-$-98.33M-$-66.39M-$-59.28M-$-50.62M
Weighted average shares outstanding$53.7M$31.8M$26.7M$25.2M$25.2M
Weighted average diluted shares outstanding$53.7M$31.8M$26.7M$25.2M$25.2M
Balance sheet
20252024202320222021
Cash and short-term investments$181.8M$121.5M$121.5M$77.3M$135.9M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$188.4M$126.1M$124.3M$80.1M$136.7M
Property, plant and equipment, net$8.86M$10.6M$12.3M$13.8M$170K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$68.2M$7.01M$0.00$0.00$0.00
Total non-current assets$80.3M$20.8M$15.5M$21.3M$180K
Total assets$268.7M$146.9M$139.8M$97.1M$136.9M
Accounts payable$4.86M$6.42M$3.79M$2.68M$3.06M
Short-term debt$2.67M$2.67M$2.6M$2.83M$0.00
Deferred revenue$0.00$0.00$0.00$0.00$50K
Total current liabilities$16.8M$22.9M$17.2M$14.4M$7.45M
Long-term debt$5.21M$7.25M$9.03M$10.7M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$5.21M$7.25M$9.03M$195.7M$185M
Capital lease obligations$7.89M$7.25M$11.6M$13.5M$0.00
Total liabilities$22M$30.1M$26.3M$210M$192.5M
Common stock$10K$0.00$0.00$0.00$0.00
Retained earnings-$-380.13M-$-280.17M-$-181.84M-$-115.45M-$-56.17M
Accumulated other comprehensive income (loss)$190K-$-100K$0.00-$-185.03M-$-185.01M
Total equity$246.7M$116.8M$113.5M-$-112.95M-$-55.6M
Total investments$187M$93.5M$0.00$0.00$0.00
Total debt$7.89M$9.92M$11.6M$13.5M$0.00
Net debt-$-55.11M-$-25.09M-$-109.83M-$-63.85M-$-135.86M
Cash flow statement
20252024202320222021
Net income-$-99.96M-$-98.33M-$-66.39M-$-59.28M-$-50.62M
Depreciation and amortization$380K$2M$1.84M$1.15M$10K
Stock-based compensation$12.1M$12.5M$3.04M$1.78M$390K
Change in working capital-$-9.52M$2.73M$1.48M$1.79M$6.04M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-1.56M$2.38M-$-180K-$-430K$3.02M
Net cash provided by operating activities-$-98.56M-$-81.15M-$-59.5M-$-54.56M-$-44.18M
Investments in property, plant and equipment-$-400K-$-480K-$-120K-$-670K-$-190K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-90.25M-$-94.08M-$-170K-$-900K-$-190K
Common stock issued$217.3M$88.7M$100.3M$330K$170K
Common stock repurchased$0.00-$-20K$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$216.8M$88.8M$103.8M$190K$150.9M
Net change in cash$28M-$-86.45M$44.1M-$-55.27M$106.5M
Cash at end of period$66.3M$38.3M$124.7M$80.6M$135.9M
Operating cash flow-$-98.56M-$-81.15M-$-59.5M-$-54.56M-$-44.18M
Capital expenditure-$-400K-$-480K-$-170K-$-900K-$-190K
Free cash flow-$-98.96M-$-81.63M-$-59.66M-$-55.46M-$-44.37M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Lexeo Therapeutics, Inc. Common Stock

        Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.

        CEO
        R. Nolan Townsend
        Employees
        59
        Beta
        1.43

        Explore

        Frequently asked questions

        What is the intrinsic value of Lexeo Therapeutics, Inc. Common Stock (LXEO)?

        InvestorsCraft does not currently publish an intrinsic value for LXEO. How the IC value is calculated.

        Is LXEO undervalued?

        InvestorsCraft does not publish an undervaluation signal for LXEO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.